Anatomical Therapeutic Chemical • J06BB21 • bezlotoxumab

J Antiinfectives for systemic use

J01 Antibacterials for systemic use

J02 Antimycotics for systemic use

J04 Antimycobacterials

J05 Antivirals for systemic use

J06 Immune sera and immunoglobulins

J06A Immune sera

J06B Immunoglobulins

J06BA Immunoglobulins, normal human

J06BB Specific immunoglobulins

J06BB01 anti-D immunoglobulin Indicated for: immunosuppression

J06BB01 anti-D specific immunoglobulin Indicated for: immunosuppression

J06BB02 tetanus immunoglobulin Indicated for: prevention of tetanus

J06BB02 tetanus immunoglobulin Indicated for: prevention of tetanus

J06BB02 human tetanus immunoglobulin Indicated for: prevention of tetanus

J06BB02 human anti-tetanus immunoglobulin Indicated for: prevention of tetanus

J06BB04 hepatitis B immunoglobulin Indicated for: chronic hepatitis B

J06BB04 human anti-hepatitis B immunoglobulin Indicated for: chronic hepatitis B

J06BB05 equine rabies immunoglobulin Indicated for: immunosuppression

J06BB05 human anti-rabies immunoglobulin Indicated for: immunosuppression

J06BB05 specific rabies immunoglobulin Indicated for: immunosuppression

J06BB09 human anti-cytomegalovirus immunoglobulin Indicated for: immunosuppression

J06BB16 palivizumab Indicated for: prevention of respiratory syncytial virus disease

J06BB21 bezlotoxumab Indicated for: prevention of recurrent Clostridioides difficile infection

J06BC Other immunoglobulins

J06BD Antiviral monoclonal antibodies

J07 Vaccines